Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingKYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingFIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson’s Disease (Phase I/II)

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingTransplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson’s Disease (Phase I/II)

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingEvaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingIltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingStudy of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingA Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingCombined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingAutologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

  • Post author:
  • Post published:March 1, 2026
  • Post category:

Continue ReadingReduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
  • Go to the previous page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 15
  • Go to the next page
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us